PolyPid Ltd. (PYPD): Price and Financial Metrics


PolyPid Ltd. (PYPD): $4.54

-0.10 (-2.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PYPD Stock Price Chart Interactive Chart >

Price chart for PYPD

PYPD Price/Volume Stats

Current price $4.54 52-week high $9.64
Prev. close $4.64 52-week low $3.92
Day low $4.48 Volume 10,300
Day high $4.65 Avg. volume 34,522
50-day MA $4.91 Dividend yield N/A
200-day MA $5.82 Market Cap 77.41M

PolyPid Ltd. (PYPD) Company Bio


PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.


PYPD Latest News Stream


Event/Time News Detail
Loading, please wait...

PYPD Latest Social Stream


Loading social stream, please wait...

View Full PYPD Social Stream

Latest PYPD News From Around the Web

Below are the latest news stories about PolyPid Ltd that investors may wish to consider to help them evaluate PYPD as an investment opportunity.

JMP Securities Thinks PolyPid’s Stock is Going to Recover

JMP Securities analyst Roy Buchanan reiterated a Buy rating on PolyPid (PYPD – Research Report) today and set a price target of $15.00. The company's shares closed last Wednesday at $4.15, close to its 52-week low of $4.01. According to TipRanks.com, Buchanan 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.3% and a 32.0% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Arbutus Biopharma, and Hookipa Pharma. Currently, the analyst consensus on PolyPid is a Moderate Buy with an average price target of $22.50.

Brian Anderson on TipRanks | February 9, 2022

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

• FDA Agreed to PolyPid Request for the Addition of an Unblinded Interim Analysis in SHIELD I once 750 Patients Complete their 30-day Follow-up• Recruitment Progressing as Planned with Approximately 680 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery. Expect to Reach 750 Enrolled Patients by End of First Quarter 2022 and Have Unblinded Interim Analysis During the Second Quarter of 2022• Recently Completed Planned 500-Patient Blinded Sample Size Reasses

Yahoo | February 9, 2022

PolyPid to Report Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 9, 2022

PETACH TIKVA, Israel, Jan. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 9, 2022. The Company will host a confe

Yahoo | January 26, 2022

PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board

Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced the appointment of Mitchel S. Be

Yahoo | January 4, 2022

PolyPid Announces Planned CEO Transition

Current EVP & CFO, Dikla Czaczkes Akselbrad, Appointed CEO, Effective July 2022PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that its Board of Directors has appointed Dikla Czaczkes Akselbrad, currently the Company’s Executive Vice President and Chief F

Yahoo | January 3, 2022

Read More 'PYPD' Stories Here

PYPD Price Returns

1-mo -12.86%
3-mo -19.50%
6-mo -25.57%
1-year -47.94%
3-year N/A
5-year N/A
YTD -20.91%
2021 -42.02%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4465 seconds.